tcmcb07
Peptideexperimental
Clinical trial activity
2 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jul 12, 2022 (NCT05529849)
Timeline
Indications
Studied for
Mechanism of action
- Melanocortin receptor 4ANTAGONIST
MC4R antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06937177 | Phase 2 | Apr 28, 2025 | Endevica Bio |
| NCT05529849 | Phase 1 | Jul 12, 2022 | Endevica Bio, Quotient |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Endevica Bio | For profit | 2 | 2 | 2 | 2022 |
| Quotient | For profit | 1 | 0 | 1 | 2022 |
2 organizations
Page 1 / 1